Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07507318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Study acronym: DEL-MRD-CHID
StatusRecruiting
PhasePhase 2
SponsorRong Tao
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Apr 1, 2026 to Jun 16, 2026
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rong Tao
7 trials monitored
See all monitored trials
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction therapy but remain ctDNA minimal residual disease (MRD)-positive. Eligible participants will receive oral chidamide 20 mg on Days 1, 4, 8, and 11 of each 21-day cycle. ctDNA MRD will be assessed every 12 weeks. Treatment will continue until two consecutive MRD-negative assessments, disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years of maintenance. The primary objectives are to evaluate ctDNA MRD negativity and 2-year progression-free survival. Secondary objectives include event-free survival, overall survival, and safety.
Trial Details
NCT Number NCT07507318
Lead Sponsor Rong Tao
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual
Enrollment 69 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov